<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2240215-B1" country="EP" doc-number="2240215" kind="B1" date="20140108" family-id="40568612" file-reference-id="315030" date-produced="20180825" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146588007" ucid="EP-2240215-B1"><document-id><country>EP</country><doc-number>2240215</doc-number><kind>B1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-09703065-A" is-representative="NO"><document-id mxw-id="PAPP154850199" load-source="docdb" format="epo"><country>EP</country><doc-number>09703065</doc-number><kind>A</kind><date>20090115</date><lang>EN</lang></document-id><document-id mxw-id="PAPP206117893" load-source="docdb" format="original"><country>EP</country><doc-number>09703065.4</doc-number><date>20090115</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140554591" ucid="US-2009031119-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>2009031119</doc-number><kind>W</kind><date>20090115</date></document-id></priority-claim><priority-claim mxw-id="PPC140550359" ucid="US-2176408-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>2176408</doc-number><kind>P</kind><date>20080117</date></document-id></priority-claim></priority-claims><dates-of-public-availability><intention-to-grant-date><date>20130405</date></intention-to-grant-date></dates-of-public-availability><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1989324499" load-source="docdb">A61L  31/14        20060101ALI20090813BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989324500" load-source="docdb">A61L  31/10        20060101AFI20090813BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989324501" load-source="docdb">A61L  31/12        20060101ALI20090813BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989324502" load-source="docdb">A61F   2/06        20130101ALI20090813BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989627887" load-source="docdb">A61F   2/90        20130101A I20130223RMEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1939998862" load-source="docdb" scheme="CPC">A61F   2/90        20130101 LI20160510BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1939999139" load-source="docdb" scheme="CPC">A61F   2/848       20130101 FI20160509BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1939999493" load-source="docdb" scheme="CPC">A61L  31/125       20130101 LI20160510BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1939999629" load-source="docdb" scheme="CPC">A61F2250/0026      20130101 LA20160510BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1940000067" load-source="docdb" scheme="CPC">A61F2220/0016      20130101 LA20160509BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1940000289" load-source="docdb" scheme="CPC">A61F2230/0078      20130101 LA20160510BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1940001139" load-source="docdb" scheme="CPC">A61L  31/10        20130101 LI20160510BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1940001144" load-source="docdb" scheme="CPC">A61F2250/0037      20130101 LA20160510BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1940002851" load-source="docdb" scheme="CPC">A61F2230/005       20130101 LA20160510BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1940003090" load-source="docdb" scheme="CPC">A61F2002/30322     20130101 LA20160510BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1940003408" load-source="docdb" scheme="CPC">A61F2002/072       20130101 LA20160510BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1940003564" load-source="docdb" scheme="CPC">A61F2002/8486      20130101 LA20160509BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1940005618" load-source="docdb" scheme="CPC">A61F2002/075       20130101 LA20160510BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1940006115" load-source="docdb" scheme="CPC">A61L  31/14        20130101 LI20160510BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1940006946" load-source="docdb" scheme="CPC">A61F2250/0039      20130101 LA20160510BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1940007086" load-source="docdb" scheme="CPC">A61F   2/07        20130101 LI20160510BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132368654" lang="DE" load-source="patent-office">STENT MIT ANTIBEWEGUNGSFUNKTION</invention-title><invention-title mxw-id="PT132368655" lang="EN" load-source="patent-office">STENT WITH ANTI-MIGRATION FEATURE</invention-title><invention-title mxw-id="PT132368656" lang="FR" load-source="patent-office">ENDOPROTHÈSE VASCULAIRE AVEC CARACTÉRISTIQUE ANTIMIGRATOIRE</invention-title><citations><patent-citations><patcit mxw-id="PCIT370828473" load-source="docdb" ucid="WO-2008019116-A2"><document-id format="epo"><country>WO</country><doc-number>2008019116</doc-number><kind>A2</kind><date>20080214</date></document-id><sources><source name="EXA" created-by-npl="N"/></sources></patcit></patent-citations></citations></technical-data><parties><applicants><applicant mxw-id="PPAR919538145" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>BOSTON SCIENT SCIMED INC</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR919541547" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>BOSTON SCIENTIFIC SCIMED, INC.</last-name></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919525441" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>CLERC CLAUDE</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919518142" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>CLERC, CLAUDE</last-name></addressbook></inventor><inventor mxw-id="PPAR919021098" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>CLERC, CLAUDE</last-name><address><street>47 Omalley Road</street><city>Marlborough MA 01752</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919520858" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>TUPIL SRI</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919535803" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>TUPIL, SRI</last-name></addressbook></inventor><inventor mxw-id="PPAR919021099" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>TUPIL, SRI</last-name><address><street>11 Alexandra Way</street><city>Acton MA 01720</city><country>US</country></address></addressbook></inventor></inventors><assignees><assignee mxw-id="PPAR919021101" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Boston Scientific Scimed, Inc.</last-name><iid>101121675</iid><address><street>One Scimed Place</street><city>Maple Grove, MN 55311</city><country>US</country></address></addressbook></assignee></assignees><agents><agent mxw-id="PPAR919021100" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Vossius &amp; Partner</last-name><iid>100751388</iid><address><street>Siebertstrasse 4</street><city>81675 München</city><country>DE</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="US-2009031119-W"><document-id><country>US</country><doc-number>2009031119</doc-number><kind>W</kind><date>20090115</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2009091899-A2"><document-id><country>WO</country><doc-number>2009091899</doc-number><kind>A2</kind><date>20090723</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS549781231" load-source="docdb">AT</country><country mxw-id="DS549866116" load-source="docdb">BE</country><country mxw-id="DS549887873" load-source="docdb">BG</country><country mxw-id="DS549796679" load-source="docdb">CH</country><country mxw-id="DS549866117" load-source="docdb">CY</country><country mxw-id="DS549868600" load-source="docdb">CZ</country><country mxw-id="DS549871668" load-source="docdb">DE</country><country mxw-id="DS549866122" load-source="docdb">DK</country><country mxw-id="DS549866123" load-source="docdb">EE</country><country mxw-id="DS549922248" load-source="docdb">ES</country><country mxw-id="DS549887926" load-source="docdb">FI</country><country mxw-id="DS549887927" load-source="docdb">FR</country><country mxw-id="DS549871669" load-source="docdb">GB</country><country mxw-id="DS549866124" load-source="docdb">GR</country><country mxw-id="DS549871674" load-source="docdb">HR</country><country mxw-id="DS549868601" load-source="docdb">HU</country><country mxw-id="DS549796680" load-source="docdb">IE</country><country mxw-id="DS549866125" load-source="docdb">IS</country><country mxw-id="DS549887928" load-source="docdb">IT</country><country mxw-id="DS549866130" load-source="docdb">LI</country><country mxw-id="DS549887929" load-source="docdb">LT</country><country mxw-id="DS549781232" load-source="docdb">LU</country><country mxw-id="DS549887938" load-source="docdb">LV</country><country mxw-id="DS549887939" load-source="docdb">MC</country><country mxw-id="DS549781241" load-source="docdb">MK</country><country mxw-id="DS549781242" load-source="docdb">MT</country><country mxw-id="DS549781243" load-source="docdb">NL</country><country mxw-id="DS549796689" load-source="docdb">NO</country><country mxw-id="DS549781244" load-source="docdb">PL</country><country mxw-id="DS549922249" load-source="docdb">PT</country><country mxw-id="DS549780314" load-source="docdb">RO</country><country mxw-id="DS549781249" load-source="docdb">SE</country><country mxw-id="DS549871675" load-source="docdb">SI</country><country mxw-id="DS549796690" load-source="docdb">SK</country><country mxw-id="DS549866131" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><description mxw-id="PDES63960436" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001"><b><u>FIELD OF THE INVENTION:</u></b></heading><p id="p0001" num="0001">The present invention relates to an intraluminal prosthesis having an anti-migration feature. More particularly, the present invention relates to a stent with a three-dimensional (3D) anti-migration exterior portion designed to prevent migration of the stent once deployed, as well as resist and/or prevent ingrowth on the stent itself to facilitate its removal at a later time.</p><heading id="h0002"><b><u>BACKGROUND OF THE INVENTION:</u></b></heading><p id="p0002" num="0002">Stents, in general, may be categorized as permanent, removable, or bioresorbable. Permanent stents are retained in place and incorporated into the lumen wall of a body by promoting ingrowth. Removable stents are removed from the body lumen when the stent is no longer desired. A bioresorbable stent may be composed of, or include, biodegradable material or bioresorbable material which may be broken down by the body and absorbed or passed from the body when it is no longer needed. In treating many bodily vessels, removable stents may be preferred over a permanent stent. For example, many esophageal stenoses procedures require stent removal at a specified date. Further, because it is difficult to predict the exact biodegrading time table of a bioresorbable stent, esophageal technology for instance, in general, has focused on the removable stent prosthesis.<!-- EPO <DP n="2"> --></p><p id="p0003" num="0003">A graft is another type of endoluminal prosthesis which is used to repair and replace body lumina. It is also known to combine a stent and a graft to form a composite stent device. Such composite stent device may provide additional support for weakened sections of a lumen.</p><p id="p0004" num="0004">The benefits and disadvantages of composite stent devices may be dependent on the extent of the coverings. For instance, bare stents can allow tissue ingrowth in the openings between the struts and therefore may have a low migration rate (undesired longitudinal movement within luminal surfaces). However, bare stents may be very difficult to remove after they have been implanted for a few weeks. In some cases, the ingrowth in the opening between the struts can continue to grow until the patency of the lumen structure is totally obstructed.</p><p id="p0005" num="0005">Partially covered stents were developed as a means to prevent or slow tissue ingrowth within portions of the body of the stent. However, these configurations also do not totally prevent tissue ingrowth. The tissue ingrowth may occur into openings of cells in the stent wall at the uncovered portions, making the stent still difficult to remove and prone to occlusion by tissue ingrowth.</p><p id="p0006" num="0006">Fully covered stents are designed to prevent tissue ingrowth along the entire length of the stent and are therefore should be much easier to remove than bare or partially covered stents even after having been implanted for an extended period of time. Covered stents may also slow the growth of tumors and fistula. However, because the covered stents generally do not include any friction inducing structure, their migration rate along the body lumens is higher<!-- EPO <DP n="3"> --> than the migration rate of bare or partially covered stents. Thus, there is a need for a stent that resists migration and can be easily removed after a given time period.</p><heading id="h0003"><b><u>SUMMARY OF THE INVENTION:</u></b></heading><p id="p0007" num="0007">The present invention is directed to intraluminal prostheses such as a fully or partially covered stent that may be repositionable and/or removable as defined in claim 1. The intraluminal prosthesis is resistant to movement or migration within a body lumen once deployed.</p><p id="p0008" num="0008">The anti-migration structure may function to lessen stent migration by roughening the outside surface of the stent, which is in contact with the inner surface of the body lumen into which it is placed. Simultaneously, the stent body may prevent or minimize the tissue ingrowth adjacent thereto. The external anti-migration structure may be formed desirably very thin and may optionally be arranged in a pattern which provides for low profile delivery device.<!-- EPO <DP n="4"> --></p><p id="p0009" num="0009">There is provided in claim 14 a method of forming a prosthesis, which includes providing a stent, and attaching a covering to the stent, the covering including an anti-migration structure which may provide anti-slip or anti-migration properties to the prosthesis. The covering is preferably a biocompatible material, for instance, a polymer which may be attached to the stent in various ways, including but not limited to being placed over the stent and adhered to the stent with use of a heat-shrink tube and heat. Other adhesion methods include placing the anti-migration structure on a stent, and spraying the stent and the anti-migration structure with a binder such as a polyurethane polymer.</p><p id="p0010" num="0010">Additionally, in accordance with the present invention, intraluminal prosthesis may include a radially self-expanding or a balloon expanding stent. The stent body may include a barrier region circumscribed by a film such as silicone to reduce tumor or ingrowth. Further, the barrier region may be combined with a fixation region of open weave construction. The stent may be resistant to migration and to tumor ingrowth, and may be configured to allow inner body lumen recovery gradually along its length after deployment.</p><p id="p0011" num="0011">Other objects and features of the invention will be evident from the following detailed description of the embodiments and practices included in the invention and from the drawings herewith.</p><heading id="h0004"><b><u>BRIEF DESCRIPTION OF THE DRAWINGS:</u></b></heading><p id="p0012" num="0012"><ul><li><figref idrefs="f0001">FIG. 1</figref> illustrates a perspective view depicting an embodiment of an intraluminal prosthesis with 3D anti-migration structure formed thereon;<!-- EPO <DP n="5"> --></li><li><figref idrefs="f0002">FIG. 2</figref> illustrates a cross-sectional view depicting the stent of <figref idrefs="f0001">Fig. 1</figref> along the line A-A;</li><li><figref idrefs="f0003">FIG. 3</figref> illustrates a perspective view of an embodiment of a stent incorporating the anti-migration structure of the present invention, without depicting the visible struts for clarity;</li><li><figref idrefs="f0004">FIG. 4</figref> illustrates a cross-sectional view of the stent along the line B-B of <figref idrefs="f0003">Fig. 3</figref>;</li><li><figref idrefs="f0005">FIG. 5</figref> illustrates a detailed view of the portion of the stent device encircled at "C" in <figref idrefs="f0004">Fig. 4</figref>;</li><li><figref idrefs="f0006">FIG. 6</figref> illustrates a side plan view of another embodiment of the present invention with no flares at either ends and disclosing filament provided integrally with the stent struts directed at a particular direction having angle "α" with respect to an axis;</li><li><figref idrefs="f0006">FIG. 7</figref> illustrates a side plan view of the stent device as shown in <figref idrefs="f0003">Fig. 3</figref>, teaching the filament forming a second angle "β" with respect to the axis;</li><li><figref idrefs="f0007">FIG. 8</figref> illustrates a side plan view of another embodiment of the present invention showing a knitted graft configuration;</li><li><figref idrefs="f0007">FIG. 9</figref> illustrates a plan view of further another embodiment of the present invention showing a spiral graft configuration;<!-- EPO <DP n="6"> --></li><li><figref idrefs="f0008">FIG. 10</figref> illustrates a plan view of yet another embodiment of the present invention showing a "checker-board" graft configuration;</li><li><figref idrefs="f0008">FIG. 11</figref> illustrates a plan view of yet another embodiment of the present invention, showing the graft on the flares only;</li><li><figref idrefs="f0009">FIG. 12</figref> illustrates a plan view of yet another embodiment of the present invention, showing the graft on the intermediate body only;</li><li><figref idrefs="f0009">FIG. 13</figref> illustrates a plan view of yet another embodiment of the present invention, showing the graft at discrete positions on the body of the stent; and</li></ul></p><heading id="h0005"><b><u>DETAILED DESCRIPTION OF THE INVENTION:</u></b></heading><p id="p0013" num="0013">The following is a detailed description depicting some embodiments of the present invention.</p><p id="p0014" num="0014"><figref idrefs="f0001">Figures 1</figref> and <figref idrefs="f0002">2</figref> depict different views of an intraluminal prosthesis 10. In one embodiment, the intraluminal prosthesis 10 includes a stent body 20 in a normal or relaxed configuration according to the present invention. The intraluminal prosthesis 10 can assume the normal or relaxed configuration when it is not subject to any external load or stress. As depicted in the cross-sectional view of <figref idrefs="f0002">Figures 2</figref> and <figref idrefs="f0004">4</figref>, the stent body 20 may be fully covered with an elastomeric membrane 22. The elastomeric membrane 22 is defined by an exterior surface 24 and an inner surface 26. Stent body 20 may include one or more wire stents 16. In one<!-- EPO <DP n="7"> --> embodiment, the exterior surface 24 may at least partially cover a wire stent 16 (shown in <figref idrefs="f0006">Figures 6 and 7</figref>). Alternatively, inner surface 26 of the elastomeric membrane may cover the wire stent 16. As illustrated in <figref idrefs="f0004">Figures 4</figref> and <figref idrefs="f0005">5</figref>, wire stent 16 may include a pair of helically wound or braided metal or polymeric struts 12 and 14, which may be separate pieces or may be formed from one integral strand. Struts 12 and 14 may be any configuration desired, and may be braided, woven, knitted, twisted, conjoined, locked, or laser cut. Optionally, the struts 12 and 14 may include any other desired elements to form the wire stent 16.</p><p id="p0015" num="0015">Referring back to <figref idrefs="f0003">Figures 3</figref> and <figref idrefs="f0004">4</figref>, stent body 20 includes several regions, including an intermediate region 32, a distal end cuff region 34 and a proximal end cuff region 35. The distal end cuff region 34 and the proximal end cuff region 35 may be shaped so as to have a wider cross-section than intermediate region 32, for example, which may be useful as an esophageal prosthetic device. Distal end cuff region 34 and proximal end cuff region 35 may include relatively wide flares 36, 37 disposed therein, which aid in forming the cross-section of the regions 34 and 35. In addition to its use as an esophageal prosthetic, the present invention may be used in any bodily vessel, such as in the coronary or peripheral vasculature, esophagus, trachea, bronchi, colon, biliary tract, urinary tract, prostate, brain, as well as in a variety of other applications in the body. These proximal and distal end flare regions 34, 35 of the present invention provide improved stent fixation, and thus, are particularly effective in resisting either proximal or distal migration of the stent body 20 itself. Flared cuffs 36, 37 may be designed with flexibility to readily conform to changes in the body lumen wall during the transmittal of bodily fluid or food. Alternatively, the present invention also envisions a stent body 20 having no flared end, or including one flared end as illustrated in <figref idrefs="f0006">Figure 6</figref>.<!-- EPO <DP n="8"> --> Stent body 20 may further include a medial sleeve disposed around the exterior of stent body 20, which may be disposed on any area of the stent body 20, including at least one of the intermediate region 32, distal end cuff region 34 and proximal end cuff region 35.</p><p id="p0016" num="0016">Generally, the exterior surface 24 of the intraluminal prosthesis 10 may be designed to be fairly smooth. The 3D structure 30 may provide an anti-migration affect to the prosthesis 10. As depicted in <figref idrefs="f0001">Figure 1</figref>, the 3D geometric structure 30 may be formed as a relief feature such as dots 32, beads (not shown), or rings 34. However, the 3D structure 30 may encompass any projection of figures or form shapes or other complex geometries which propel structural irregularity over the smooth exterior surface 24. When formed with the 3D structure 30 disposed over the smooth exterior surface 24, the stent body 20 is given an uneven contoured irregularity over the smooth surface 24, which may act as an added frictional point between the stent body 20 and the body lumen into which the stent body 20 is disposed. The added frictional interaction between the exterior surface 24 of the stent body 20 and the body lumen, facilitates anti-migration functionality, thus preventing or minimizing the movement of overall intraluminal prosthesis 10 in the body lumen. As will be appreciated by one of skill in the art, minimizing the movement of an intraluminal prosthesis 10 while in the body lumen is highly desired for both efficacy and safety reasons.</p><p id="p0017" num="0017">The 3D structure 30 may be configured to accommodate various tolerances in delivery systems which are to be used with the stent body 20. For instance, a stent body 20 is depicted in its relaxed or normal configuration in <figref idrefs="f0003">Figure 3</figref>. As depicted, the intermediate region 32<!-- EPO <DP n="9"> --> may have a diameter of about 20 mm, and the cuff of the proximal region 34 and/or the cuff of the distal end region 35 may have a diameter of about 30 mm. In this particular embodiment, the struts 12, 14 forming the wire stent 16 may have a diameter of about 0.22 mm or less. The 3D structure 30 may preferably have a cross section of less than approximately I mm. This tolerance ensures that the overall diameter increase of the delivery device is kept, for instance, less than 2 mm (assuming one 3D structure 30 on opposed sides of the stent body 20). However, the present invention is not limited by the exemplary dimension tolerance. The total diameter may vary according to usage of the particular delivery device in a particular vessel. For instance, the dimensional tolerance for esophageal stent may be different from a coronary stent.</p><p id="p0018" num="0018"><figref idrefs="f0003">Figure 3</figref> depicts yet another embodiment of the present invention in which the 3D structure 30 is not integrally formed with the elastomeric membrane 22. As depicted in <figref idrefs="f0003">Figure 3</figref>, a thin discrete layer including strands of anti-migration filaments 40 may be disposed on the exterior surface 24. In one particular embodiment, the anti-migration structure layer 40 forms a pattern helically expanded about the exterior surface 24 of the intraluminal prosthesis 10. According to one embodiment of the invention, the anti-migration structure layer 40 may feature a plurality of individually rigid but elastically flexible anti-migration filaments 42, 44. Each filament 42, 44 may extend circumferentially in a helical configuration around the exterior surface 24. In some embodiments, the anti-migration filaments 42, 44 may span across a common longitudinal axis 18 of the stent body 20.<!-- EPO <DP n="10"> --></p><p id="p0019" num="0019">In another embodiment, the stent body 20 may be provided with the first set of filaments 42 having a common direction of winding but circumferentially displaced relative to each other. In this embodiment, the first set of filaments 42 may be configured to cross a second set of filaments 44 also circumferentially displaced relative to each other but winding in substantially opposite direction. In this embodiment, the stent body 20 is sufficiently configured to have anti-migration properties, as provided by the crossed filaments 42, 44. The directions of the filaments 42, 44 for the present invention are not limited by the above example, and also may extend lengthwise or perpendicular to the longitudinal axis 18. Further, the filaments 42, 44 may change direction at random locations, for example, they may be curved or wavy at random.</p><p id="p0020" num="0020">The device 10 of the present invention may encompass a 3D structure 30 configured to flex along certain selective dimensions. For instance, the 3D structure 30 may include an anti-migration structure layer 40, which may be flexible in a radially outward direction of the stent body 20. In addition, the anti-migration structure layer 40 may be rigid in the longitudinal direction 18. The radial flexibility of anti-migration structure layer 40 as well as the removable stent body 20 may allow the intraluminal prosthesis 10 to be easily compressed into a delivery device. Further, the rigidity of anti-migration structure layer 40 in the longitudinal direction 18 is useful to ensure anti-migration functionality once the stent body 20 is positioned within a body lumen. The anti-migration structure layer 40 may impart such abrasive/frictional force against the interior surface of a body lumen that it will resist its longitudinal migration within the body lumen.<!-- EPO <DP n="11"> --></p><p id="p0021" num="0021">Various methods of forming the intraluminal prosthesis 10 are provided herein. In one embodiment, during the fabrication process of the stent body 20, the anti-migration structure layer 40 may be added to the wire stent 16 after the outer surface 24 is disposed on the wire stent 16.</p><p id="p0022" num="0022">In one embodiment, depicted in <figref idrefs="f0005">Figure 5</figref>, the adherent anti-migration structure layer 40 may include filaments 42, 44 having smaller diameter than the diameter of the struts 12, 14. In an alternate embodiment, the filaments 42, 44 may have larger diameters than the struts 12, 14. Further, some filaments 42, 44 may have smaller diameters than some struts 12, 14, while other filaments 42, 44 may have a larger diameter than some struts 12, 14. The present invention encompasses filament and stent body diameter of all ranges related to their uses. For instance, in the exemplary esophageal application, the anti-migration structure layer 40 may be formed with diameter less than 0.60 mm wide. Such dimension may ensure that it does not hinder the loading and removal of the stent body 20, while still remaining effective in its anti-migration functionality.</p><p id="p0023" num="0023">If desired, the anti-migration structure layer 40 may have a particular angle arrangement with respect to the longitudinal axis 18 of the device 10. As illustrated in <figref idrefs="f0006">Figure 6</figref> of the drawings, the filaments 42, 44 of the anti-migration structure layer 40 may be helically<!-- EPO <DP n="12"> --> wrapped or arranged around the stent body 20 at a first angle alpha (α). The angle α may be selectively placed to be non-congruent to a second angle beta (β), as seen in <figref idrefs="f0006">Figure 7</figref>. This pattern of construction may allow the prosthesis 10 to be thin-walled, compliant, and more flexible, as it provides structural integrity while using less covering in the form of the anti-migration structure layer 40. Alternatively, the filaments 42, 44 may be angled at a different angle β, which may provide a more perpendicular frictional force as compared to angle α, between the anti-migration filament windings and longitudinal axis 18. Thus placed, the anti-migration structure layer 40 may allow enhanced securement of the stent body 20 to the body lumen using less material than previously used in prostheses of this type. Thus, a particular angular arrangement of the filaments 42, 44 of the anti-migration structure layer 40 may allow for a more flexible and thinner composite prosthesis compared to a wider angled structure layer. Both angles α and β may equal any value ranging from 0° to 180° with respect to the longitudinal axis 18.</p><p id="p0024" num="0024">Yet another advantage of the anti-migration structure layer 40 being disposed on the elastomeric membrane 22 is that it may provide structural reinforcement along the stent body 20. This reinforcement may enable the wire stent 16 to be constructed with a reduced angle of struts 12, 14. As used herein, the angles between the struts 12 and 14 is measured based on the strut incline deviation from the longitudinal axis 18 of the wire stent 16. <figref idrefs="f0006">Figures 6 and 7</figref>, in particular, illustrate a low angle α and a high angle β for the struts 12, 14 and the filaments 42, 44, respectively. In each case, the wire stent 16 may be oriented with its axial length in the horizontal direction.<!-- EPO <DP n="13"> --></p><p id="p0025" num="0025">In prior art applications, an angle of 45° from the longitudinal axis 18 may have been considered a lower practical limit for the angle of a mesh or open weave wire stent 16. Employing the present invention, however, may enable a reduction of the braid angle to as low as 35 degrees from the longitudinal axis 18. The advantage of a lower angle for the struts 12, 14 resides in the fact that the angle may contribute to the ratio of stent axial shortening to its radial increase structure. As the stent expands, either through use of self-expanding materials or through the assistance of a balloon, a lower angle facilitates greater radial expansion of the stent body 20. With a reduced braid angle, upon expansion, there may be less axial shortening for a given radial expansion. Due to the reduced axial "drift", the stent body 20 may be more accurately positioned within the body lumens during its deployment. Thus, the profile of an anti-migration structure layer 40 or an adhesive layer 48, in combination with the stent 16, may resist the extraneous stretching and assist in the precise positioning of the composite intraluminal prosthesis 10 inside a body lumen.</p><p id="p0026" num="0026">Various other parameters of the structures of the anti-migration structure layer 40 may be altered to control the migration of the stent in a body lumen. For instance, the orientation of the filaments 42, 44 may be positioned in a direction that approximates a substantially perpendicular direction in relation to the longitudinal axis 18. The substantially perpendicular orientation of the filaments 42, 44 may further maximize migration resistance. The configuration and compositional makeup of the filaments 42, 44, the manner in which the filaments 42, 44 are attached, as well as the thickness of the filaments 42, 44 are some migration controlling parameters which shall be discussed below.<!-- EPO <DP n="14"> --></p><p id="p0027" num="0027">Referring now to <figref idrefs="f0006 f0007 f0008 f0009">Figures 7 through 13</figref>, several embodiments of the anti-migration structure layer 40 are shown, with the elements of the anti-migration structure layer 40 placed in various different pattern arrangements with respect to the removable stent body 20. Note that the orientation and configuration of anti-migration structure layer 40 may be varied to resist migration of the stent body 20 within the body lumen. The anti-migration structure layer 40 may have a diameter that is less than the diameter of the stent body 20, or may have a diameter that is greater than the diameter of the stent body 20. <figref idrefs="f0006">Figure 7</figref> depicts a fully covered stent body 20, wherein the stent body 20 is substantially fully covered with an anti-migration structure layer 40. In such embodiment, a braided anti-migration structure 40 could be made so as to match the strut braiding angle and expand/compress in concert with the struts 12, 14. As described above, the anti-migration structure layer 40 may be formed on the stent body 20 itself prior to applying an elastomeric membrane 24. Such composite anti-migration stent structure may be formed at the same angle and at same phase with each other. Alternatively, the anti-migration filaments 42, 44 may be at a different phase from the struts 12, 14. Further, the number of filaments 42, 44 in relation to the stent struts 12, 14may be varied, as desired by the user. The filaments 42, 44 of the anti-migration structure layer 40 may wind at more than one angle with respect to the longitudinal axis 18. The bisecting pattern of strand filaments 42 and 44 depict different orientation (as well as the different angles) with respect to longitudinal axis 18. When each filament 42,44 may intersect the other filament 42, 44, the intersection where the strand filaments 42, 44 bisect each other may be defined as nodes 49. These nodes 49 may form the adhesive positions for the filaments 42, 44. In another embodiment, filaments 42, 44 may be sintered to themselves at the segment where they intersect at node 49, as well as to the tubular prosthesis body 20 itself.<!-- EPO <DP n="15"> --> Any means to secure the filaments 42, 44 to the intraluminal prosthesis 10 may be used, and may include the use of adhesives or sintering as desired.</p><p id="p0028" num="0028"><figref idrefs="f0007">Figure 8</figref> depicts yet another embodiment of the present invention, which is configured with a knitted anti-migration pattern on a stent body 20 of prosthesis 10. The anti-migration structure layer 40 may form loops at wave-like peaks 45 in order to secure the anti-migration layer 40 to the outer surface 24. The windings may be arranged on the nested stent body 20 in such a manner that upper wave-like peaks 45 may be nested within successive lower wave-like peaks 47 of adjacent windings. This knitting configuration may provide for subsequent anti-migration filaments 42, 44 on preceding structures where the preceding peaks 47 may intersect the subsequent peaks 45 to form elbow loops of coincidence or eyelet nodes of nodes 49. One of the main advantages of a knitted structure is that its orientation may be configured in a direction substantially perpendicular to the direction of the longitudinal axis 18. This pattern may provide greater frictional resistance to migration within the body lumens.</p><p id="p0029" num="0029"><figref idrefs="f0007">Figure 9</figref> illustrates an anti-migration structure layer 40 secured around the stent body 20 in a spiral fashion. The spiral pattern of the anti-migration structure layer 40 defines a plurality of spaced apart windings 51. Spaced apart windings 51 are disposed at a first angle with respect to the longitudinal axis 18 of the stent body 20. Successive windings 51 are positioned at a particular angle (as depicted with directional arrow 53) theta "γ" with respect to the longitudinal axis 18. As can be noted in the Figures, spiral winding 51 may be patterned in a straight line or in a wavy pattern analogous to a moire design. A wavy pattern may provide additional structural irregularity over the exterior surface 24.<!-- EPO <DP n="16"> --></p><p id="p0030" num="0030"><figref idrefs="f0008">Figure 10</figref> depicts a loosely woven anti-migration structure layer 40, which is repeatedly wound as both ring filament winding 57, 59 and longitudinal filament winding 55 substantially parallel with respect to the longitudinal axis 18 in a checker-board pattern. As depicted, the anti-migration filament 55 may be wound along the axis 18 and around the circumference of the stent body 20. <figref idrefs="f0008">Figure 10</figref> also depicts parallel windings of the filament 57 in such a manner that each upper winding 57 and lower winding 59 of adjacent windings are parallel across the stent body 20. When the windings 55, 57, 59 of the anti-migration structure layer 40 are orientated in two different directions substantially perpendicular to each other and with respect to the longitudinal axis 18 as depicted in <figref idrefs="f0008">Figure 10</figref>, the anti-migration features may minimize not only the lateral migration but also prevent rotational migration as well. The anti-migration filament 57 may intersect other filament 55 to form nodes of intersection 61. The anti-migration structure layer 40 may be adhered to itself at nodes 61, or may be adhered to itself, as well as to the exterior surface 24 of the prosthetic device 10. Preferably, the anti-migration structure layer 40 may be sintered to itself at the segment it intersects, as well as to the tubular prosthesis at nodes 61, but other means for attachment, such as adhesives, are contemplated.</p><p id="p0031" num="0031"><figref idrefs="f0008">Figure 11</figref> illustrates another alternative stent body 20 where the anti-migration structure layer 40 is disposed primarily on the stent flares 36, 37. This configuration is particularly suited for esophageal placement, but may be used in any desired application. In this embodiment, the filaments 63 of the prosthesis 10 may be constructed to further strengthen the frictional force between the flare portions 36, 37 and the body lumen. Further, the strand filaments 63,<!-- EPO <DP n="17"> --> may be of mesh or open weave construction, or they may comprise multiple braided and helically wound strands. The anti-migration structure layer 40 may have a first arrangement at one end and a second arrangement at the opposite end, or it may have the same arrangement at each end. Further, there may be an anti-migration structure layer 40 disposed at one end, and no anti-migration structure layer 40 disposed at the opposite end.</p><p id="p0032" num="0032"><figref idrefs="f0009">Figure 12</figref> illustrates a stent body 20 wherein the anti-migration structure layer 40 is applied only to the intermediate body 32. In this aspect of the invention, the anti-migration structure layer 40 may be applied selectively to the intermediate body 32 so as to limit or slow the expansion of the intermediate body 32. Because the end flare portions 36, 37 are free of the anti-migration layer 40 in this particular embodiment, these flare portions 36, 37 may be free to engage the lumen or blood vessel wall. One advantage of this construction is that the end portions may be positioned to engage relatively healthy tissue surrounding the site of the stenosis or structural defect, avoiding trauma to the weakened tissue.</p><p id="p0033" num="0033"><figref idrefs="f0009">Figure 13</figref> depicts a stent body 20 where the anti-migration structure layer 40 is applied at various locations 65 on the stent body 20. By having such a configuration, the distance between two threads can be controlled and optimized so that the outer surface is roughened to create controlled friction for anti-migration purpose.</p><p id="p0034" num="0034">It is important to note that, in general, the anti-migration structure layer 40 may be applied to a bare or partially covered stent body, as well as on top of a stent-graft (such as an ePTFE<!-- EPO <DP n="18"> --> covered stent) combination. In addition, the anti-migration structure layer 40 may be applied to a self-expanding or a balloon expandable stent. Further, although the stent embodiments above have been exemplified with two flares 36, 37, the same invention can apply to stents with one or no flares as seen in <figref idrefs="f0006">Figure 6</figref>. Further, although only two struts 12, 14 and two filaments 42, 44 have been identified in this description, it should be understood that any number of struts may be used to form the wire structure 16, and any number of filaments may be used to form the anti-migration structure layer 40. In addition, any of the stent body 20, elastomeric membrane 22, or the anti-migration structure layer 40, and combinations thereof, may be radiopaque.</p><p id="p0035" num="0035">In general, coating of the device 10 with an elastomeric membrane 22 is designed to enhance patency (state of being open). In addition, the tubular coating may resist tumor ingrowth. The thickness of the elastomeric membrane 22 may be in the range of 0.003-0.01 inches (0.075-0.25 mm). However, such elastomeric membrane 22 may also be up to a range of 0.001 - 0.1 inches (0.0254-2.54 mm). In some embodiments, the elastomeric membrane 22 may include a silicone film layer. The elastomeric membrane 22 may be disposed onto the outer surface of the stent body 20 by any desired means, including by placing the elastomeric membrane 22 onto the surface, by extruding the elastomeric membrane 22 onto the outer surface, or by dipping or spraying the elastomeric membrane 22 onto the outer surface. In the case of elastomeric membrane 22 formed by dipping, the thickness of the elastomeric membrane 22 may be controlled primarily by the number of dip coating applications. In particular, any number from one to about ten dip coatings (and preferably three to five dip coatings) of the stent body 20 may result in a thickness within a desired range. The elastomeric membrane 22<!-- EPO <DP n="19"> --> of the prosthesis 10 may also be formed of polytetrafluoroethylene (PTFE/ePTFE). Considered alone, the coating should provide an effective barrier to tissue ingrowth. In addition, the elastomeric membrane 22 may be elastic, and thus may radially expand like the remainder of stent body 20. Thus, silicone construction, in general, may be engineered to exert constant, gentle pressure to help adapt to normal luminal patency, for instance of esophageal peristalsis as its smooth inner surface helps facilitate passage of fluid. Optionally, the ends of the prosthesis 10 may also be reinforced by continuous polymeric film to help resist hyperplasia.</p><p id="p0036" num="0036">Desirably, any or all of the components of the intraluminal device 10, including but not limited to the elastomeric membrane 22, the struts 12, 14, the filaments 42, 44 or the material of the anti-migration structure layer 40 are made of a biocompatible material, including metals or polymeric materials. Any materials may be used in the forming of these elements. In one embodiment, the elastomeric membrane 22 preferably includes silicone, but other materials having elastomeric and biocompatible characteristics are also envisioned by the present invention. Further, the various struts 12, 14 that form the stent body 20 and/or the filaments 42, 44 that form the anti-migration structure 40 may include a monofilament or multi-filament structure. By way of example and not limiting the invention in any manner, other materials for any or all of the components of the device 10 may include polyurethane (PU), polyethylene (PE), polytetrafluoroethylene (PTFE), or expanded polytetrafluoroethylene (ePTFE). Textile or fabric constructions comprising of PTFE or ePTFE yarns, filament extrusions, or mesh may also be employed.<!-- EPO <DP n="20"> --></p><p id="p0037" num="0037">Similarly, the three-dimensional geometric structure 30 or the elastomeric membrane 22 may also be formed of any combined material among other choices inclusive of silicone, PU, PE or ePTFE. Also, the 3D structure could be made out of a material that is different from the material used to cover the stent. Furthermore, it may also be desirable to coat the stent body 20 with an additional thin layer of polymeric covering material to improve the adhesion of any 3D structures 30 or the anti-migration structure layer 40. In this embodiment, any 3D or anti-migration structure 30 may be disposed on the outer surface of the polymeric covering material along any length of the polymeric covering material. Further, the 3D structure 30 or anti-migration structure layer 40 may be disposed along any desired length of the prosthesis. In addition to the polytetrafluoroethylene (PTFE/ePTFE) as mentioned above, examples of suitable biocompatible polymers also include, and are not limited to, polyolefins such as high density polyethylene (HDPE) and polypropylene (PP), polyolefin copolymers and terpolymers, polyethylene terephthalate (PET), polyesters, polyamides, polyurethaneureas and polycarbonates, polyvinyl acetate, thermoplastic elastomers including polyether-polyester block copolymers, polyvinyl chloride, polystyrene, polyacrylate, polymethacrylate, polyacrylonitrile, polyacrylamide, silicone resins, combinations and copolymers thereof, and the like. Other useful coating materials include any suitable biocompatible coating. Non-limiting examples of suitable coatings include hydrophilic materials, hydrogels, and the like. Useful hydrophilic coating materials include, but are not limited to, alkylene glycols, alkoxy polyalkylene glycols such as methoxypolyethylene oxide, polyoxyalkylene glycols such as polyethylene oxide and its copolymers, polyethylene oxide/polypropylene oxide copolymers, polyalkylene oxide-modified polydimethylsiloxanes, polyphosphazenes, poly(2-ethyl-2-oxazoline), homopolymers and copolymers of (meth) acrylic acid, poly(acrylic acid),<!-- EPO <DP n="21"> --> copolymers of maleic anhydride including copolymers of methylvinyl ether and maleic acid, pyrrolidones including poly(vinylpyrrolidone) and its derivatives, homopolymers and copolymers of vinyl pyrrolidone, poly(vinylsulfonic acid), acryl amides including poly(N-alkylacrylamide), poly(vinyl alcohol), poly(ethyleneimine), poly(carboxylic acids), methyl cellulose, carboxymethylcellulose, hydroxypropyl cellulose, polyvinylsulfonic acid, water soluble nylons, heparin, dextran, modified dextran, hydroxylated chitin, chondroitin sulphate, lecithin, hyaluranon, combinations and copolymers thereof, and the like. Other non-limiting examples of suitable hydrogel coatings include hydroxyethylacrylates or hydroxyethyl(meth)acrylates; polyethylene maleic anhydride, combinations and copolymers thereof, and the like. Additional details of suitable coating materials and methods of coating medical devices with the same may be found in <patcit id="pcit0001" dnum="US6447835B"><text>U.S. Patent Nos. 6,447,835</text></patcit> and <patcit id="pcit0002" dnum="US6890348B"><text>6,890,348</text></patcit>, assigned to the common assignee as the assignee of the present invention. Other useful synthetic biocompatible polymeric materials include, but are not limited to, polyesters, including polymethylacetates, naphthalane dicarboxylene derivatives, and silks. The polymeric materials may further include a metallic, a glass, ceramic or carbon constituent or fiber. Useful and nonlimiting examples ofbioabsorbable or biodegradable polymeric materials include poly(L-lactide) (PLLA), poly(D,L-lactide) (PLA), poly(glycolide) (PGA), poly(L-lactide-co-D,L-lactide) (PLLA/PLA), poly(L-lactide-co-glycolide) (PLLA/PGA), poly(D,L-lactide-co-glycolide) (PLA/PGA), poly(glycolide-co-trimethylene carbonate) (PGA/PTMC), polydioxanone (PDS), Polycaprolactone (PCL), polyhydroxybutyrate (PHBT), poly(phosphazene) poly(D,L-lactide-co-caprolactone) PLA/PCL), poly(glycolide-co-caprolactone) (PGA/PCL), poly(phosphate ester) and the like. Some other materials which may be used as the filament<!-- EPO <DP n="22"> --> include, but are not limited to Polyether ether ketone (PEEK), fluorinated ethylene propylene (FEP), and polyimide (PI), polybutylene terephthalate (PBT), polyurethane rubber (PUR), and silicone rubber. Tape, thread, ribbon, or other elongate members may also be used. According to one embodiment of the invention, at least one and preferably all extrusions is composed of one or more commercially available grades of polygluconate, polylactic acid-polyethylene oxide copolymers, modified cellulose, collagen, poly(hydroxybutyrate), polyanhydride, polyphosphoester, poly(amino acids), poly(alpha-hydroxy acid) or related copolymers materials. Further, the stent body 20 may include materials made from or derived from natural sources, such as, but not limited to collagen, elastin, glycosaminoglycan, fibronectin and laminin, keratin, alginate, combinations thereof and the like.</p><p id="p0038" num="0038">In addition to or in contrast to the polymeric materials set forth above, the stent body 20, inclusive of struts 12, 14, and/or the anti-migration structure layer 40, inclusive of the filaments 42,44, may include improved external imaging properties under magnetic resonance imaging (MRI) and/or ultrasonic visualization techniques. MRI is produced by complex interactions of magnetic and radio frequency fields. Materials for enhancing MRI visibility include, but not be limited to, metal particles of gadolinium, iron, cobalt, nickel, dysprosium, dysprosium oxide, platinum, palladium, cobalt based alloys, iron based alloys, stainless steels, or other paramagnetic or ferromagnetic metals, gadolinium salts, gadolinium complexes, gadopentetate dimeglumine, compounds of copper, nickel, manganese, chromium, dysprosium and gadolinium. To enhance the visibility under ultrasonic visualization, the various components of the prosthetic device 10 may include ultrasound resonant material, such as but not limited to gold. Further, the stent body 20 and/or the anti-migration<!-- EPO <DP n="23"> --> structure layer 40 may be made from polymeric materials which may also include radiopaque materials, such as metallic-based powders or ceramic-based powders, particulates or pastes which may be incorporated into the polymeric material. Metallic complexes useful as radiopaque materials are also contemplated. The stent body 20 and/or the anti-migration structure layer 40 may be selectively made radiopaque at desired areas along the stent or made be fully radiopaque, depending on the desired end-product and application.</p><p id="p0039" num="0039">Further, portions of the stent body 20 and/or the anti-migration structure layer 40, for example stent struts 12, 14 and filaments 42, 44, respectively, may have an inner core of iridium or combination of thereof and an outer member or layer of Nitinol to provide a composite filament for improved radiopaqueness or visibility. For example, the radiopaque material may be blended with the polymer composition from which a polymeric wire is formed, and subsequently fashioned into the stent body 20 and/or the anti-migration structure layer 40 as described herein. Alternatively, the radiopaque material may be applied to the surface of the metal or polymer strut 12, 14 or filament 42, 44. In addition, any component of the device 10, including the 3D structure, or any additional elements beyond the stent body 20 and anti -migration structure layer 40 may include one or more radiopaque elements. Various radiopaque materials and their salts and derivatives may be used including, without limitation, bismuth, barium and its salts such as barium sulfate, tantalum, tungsten, gold, platinum and titanium, to name a few. Additional useful radiopaque materials may be found in <patcit id="pcit0003" dnum="US6626936B"><text>U.S. Patent No. 6,626,936</text></patcit>.<!-- EPO <DP n="24"> --></p><p id="p0040" num="0040">Further, the materials of the anti-migration structure layer 40 can be chosen to provide gradual and controlled expansion of the stent body 20 over time. Specifically, the expansion characteristics of the anti-migration structure layer 40 can be chosen to differ from the expansion characteristics of the wire stent 16. In addition, the construction of the anti-migration structure layer 40 and its configuration about the stent body 20 can be chosen in such a manner as to allow for partial expansion of the stent to an intermediate diameter; the construction may allow further expansion of the stent body 20 to transpire over a longer period of time to its fully self-expanding diameter. Such combination may be employed in combination with the individual filaments 42, 44 or variation of different threads which make up a strand suture or yarn, or multiple sutures, each having a different expansion rate. The materials providing expansion characteristics may be applied to the stent body 20 at any desired location, including the intermediate region 32, distal cuff region 34, proximal cuff region 35, and combinations thereof.</p><p id="p0041" num="0041">Although polymeric and other materials are envisioned, the anti-migration filaments 42, 44 may preferably be comprised of an elongate textile material. Use of textile fibers obviates the need to shape and mold a device into its ultimate working configuration. Many fibers have proven to be biocompatible with body tissues. The term "textile material" in this disclosure is meant to include any material which may be used to combine with other pieces of the same material to become part of a larger piece of fabric. Examples of such textile materials include Nylon and polyester. Polyester is commonly used because it is available in a wide range of linear densities and its low moisture absorption also gives good resistance to fast deterioration. Polyurethane is yet another polymer which may be, due to its elasticity.<!-- EPO <DP n="25"> --></p><p id="p0042" num="0042">Alternatively, the anti-migration structure layer 40 may be formed of a variety of other materials having similar properties as well. In order to comply with changes in stent dimensions between the compressed and expanded stent, the fibers may be elastomeric. Such an elastomer may comprise, for instance, LYCRA™ or a polyurethane fiber.</p><p id="p0043" num="0043">Graft material selection is not limited to those materials listed above, but may include others that are conducive to the biocompatibility, distensibility and microporosity requirements of endovascular applications. For example, biodegradable filament extrusions sold under the tradename MONOCRYL™ (Ethicon, Inc., Somerville, New Jersey) may be used. Alternatively, although thread-like or suture structures have been specifically mentioned as examples, this invention contemplates the use of any material and configuration capable of serving as constraining elements. Synthetic biocompatible, biodegradable polymers, such as those which break down to substantially non-toxic compounds which are readily absorbed and/or eliminated by the body, may also be useful. The present invention is not limited to these materials for the monofilament or multifilament struts 12, 14 or filaments 42, 44. In addition, the monofilament or multifilament struts 12, 14 or filaments 42, 44 according to the present invention can be comprised of any materials and structures mentioned above including braided, twisted or other methods.</p><p id="p0044" num="0044">Any component of the prosthetic device 10, and particularly the anti-migration structure layer 40, may also include a therapeutic agent that may be released into the body over time. Useful therapeutic agents or drugs include but not limited to, anti-platelets, anti-thrombins, antitumor<!-- EPO <DP n="26"> --> drugs, anti-hyperplasia agents, anti-plaque building agents, cytostatic agents, and anti-proliferative agents, or other drugs for a specific purpose. This may also include agents for gene therapy. The therapeutic agent or drug is preferably selected from the group of therapeutic agents or drugs consisting of urokinase, dextrophenylalanine proline arginine chloromethylketone (PPack), enoxaprin, angiopeptin, acetylsalicylic acid, paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, sulfasalazine, mesalamine, sodium heparin, low molecular weight heparin, hirudin, prostacyclin and prostacyclin analogues, dextran, glycoprotein IIb/IIIa platelet membrane receptor antibody, recombinant hirudin, thrombin inhibitor, calcium channel blockers, colchicine, fibroblast growth factor antagonists, fish oil, omega 3-fatty acid, histamine antagonists, HMG-CoA reductase inhibitor, methotrexate, monoclonal antibodies, nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitor, seramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine and other PDGF antagonists, alpha-interferon and genetically engineered epithelial cells, and combinations thereof. The foregoing list of therapeutic agents is provided by way of example and is not meant to be limiting, as other therapeutic agents and drugs may be developed which are equally applicable for use with the present invention.</p><p id="p0045" num="0045">Other features, which may be included with any components of the intraluminal prosthesis 10 of the present invention include surface modification components, which may be used for ultrasound, cell growth or therapeutic agent delivery, varying stiffness of the stent or stent components, varying geometry, such as tapering, flaring, bifurcation and the like, varying material, varying wire cross-section, varying geometry of stent components, for example tapered stent filaments, varied cross-section, wire cross-section and the like.<!-- EPO <DP n="27"> --></p><p id="p0046" num="0046">The invention also encompasses various means of manufacturing the intraluminal prosthesis. As an example, and not limiting in anyway, the wire stent 16 of this intraluminal prosthesis 20 may be circumscribed, i.e. completely covered, with a continuous polymeric film, preferably silicone or polyurethane. The polymeric film may be applied to the wire stent 16 by any desired means, including by spraying or dip-coating methods. In one embodiment, the polymeric film may be applied by dip coating of wire stent 16, in which event the film initially covers at least one of the distal or proximal cuffs 34, 35. When a partially covered stent is desired, the polymeric film may be removed from that cuff prior to using the stent body 20.</p><p id="p0047" num="0047">Generally, when incorporated into the device 10, the 3D geometric structure 30 may also be integrally preformed with the elastomeric membrane 22. In another method, the 3D geometric structure 30 may be applied to the surface of the stent body 20 directly. In an alternate embodiment, the 3D structure 30 may be disposed on the membrane 22 after the membrane 22 has been disposed onto the stent body 20 by any means desired, such as by molding, attaching, or other methods known by a person skilled in the art. For instance, the 3D structure 30 can be machined, laser etched, sprayed or even molded on to the stent body 20 or the elastomeric membrane 22. In addition, the struts 12 and 14 may be constructed with contours, effectively fashioning the 3D structure 30 to the elastomeric membrane 22. If desired, the 3D structure 30 may be arranged in any desired pattern, such as a helical pattern, an open weave pattern, an open knit pattern, a molded pattern, and combinations thereof<!-- EPO <DP n="28"> --></p><p id="p0048" num="0048">In another manufacturing method for the intraluminal prosthesis 10, the process involves continuous fiber winding. In this embodiment, a polymer melt, solution or dispersion is extruded through a small orifice to form a polymeric fiber on the surface of the stent body 20. The polymeric fiber can be arranged in a structured pattern or in random pattern similar to a non-woven structure such as Tyvek™. Alternatively, a structured pattern can be obtained by continuously winding the fiber onto a rotating mandrel, fiber binding taking place on the surface of the stent body 20 in a particular design as described above. Although this process may be especially useful with polymers that are good fiber formers, the present invention is not so limited. The covered stent body 20 may be additionally cured by heat/pressure to improve the binding process. Additionally, the adhesion between the random fiber pattern and the stent body 20 may be improved by applying a pressure between the stent body 20 and the fiber. This may be accomplished, for instance, with a heat-shrink sleeve.</p><p id="p0049" num="0049">As a further illustration of the structure and the method described above, <patcit id="pcit0004" dnum="US4798606A"><text>U.S. Pat. No. 4,798,606 assigned to Corvita </text></patcit>describes a coiled monofilament polymer structure, and <patcit id="pcit0005" dnum="US6056993A"><text>U.S. Pat. No. 6,056,993 to Anderson et al.</text></patcit>, assigned to Schneider, USA, describes several ways to produce a porous polymeric graft.</p><p id="p0050" num="0050">If desired for certain polymers, such as silicone, an electric field may be applied between the orifice and the stent body 20 to aid in a process, known as electrostatic spraying. In this technique, a polymer melt, solution or dispersion is extruded through a fine orifice and directed towards a rotating mandrel. The polymer is attracted to the mandrel by the applied<!-- EPO <DP n="29"> --> voltage. The mandrel is then struck with a plurality of short polymeric fibers that eventually coat the mandrel.</p><p id="p0051" num="0051">In some cases, the short polymeric fibers may tend to coalesce, leading to a low porosity. This coalescence may be overcome by spinning at least one water insoluble fibrous component together with at least one separate water soluble fibrous component. The water soluble fibrous component may then be washed out leaving the desired porosity on the external surface. Of course, the present invention is not so limited by the above example of continuous fiber winding method. The present invention encompasses many variations of the winding method. For instance, several spinnerets may be used simultaneously on the mandrel to provide effective coating.</p><p id="p0052" num="0052">In another embodiment, a salt dilution method may be utilized to provide the 3D structure 30. In this method, a water insoluble resin is mixed with a water soluble salt. The salt resin combination is applied to the stent body 20, and then the salt may be rinsed out with hot water leaving a porous resin structure on which the 3D structure 30 is adhered.</p><p id="p0053" num="0053"><figref idrefs="f0003">Figure 3</figref> depicts the filaments 42, 44 of the anti-migration structure layer 40 which are disposed on the exterior surface of the stent body 20 along its substantial length. The term "adhered" as used in this disclosure refers to the attaching of one component (such as the anti-migration structure layer 40) to another component (such as the tubular stent body 20) in any desired manner. This term, "adhere" includes without limitation, lamination, thermally adhering, sintering, RF welding, attaching with an adhesive, and any combination of the<!-- EPO <DP n="30"> --> above. Sintering, as used in the present disclosure means heating the composite prosthesis to a temperature below its melting point, yet sufficient to thermally adhere the prosthesis. The heat of sintering differs for different materials. An adhesive may be used in conjunction with the sintering process. Alternatively, the filament(s) may be adhered with an adhesive without sintering.</p><p id="p0054" num="0054">Other ways to attach the anti-migration structure layer 40 to the stent body 20 in lieu of the electrostatic method or the extrusion method are contemplated herein. For instance, such as that seen in <figref idrefs="f0005">Figure 5</figref>, an adhesive layer 48 such as polymer like polyurethane may be applied to the exterior surface 24 of the stent body 20. The anti-migration filament structure layer 40 may be placed on top or below the adhesive layer 48. In some embodiments, the adhesive layer 48 can be sprayed or coated to the outer surface 24 and/or the stent body 20 at any desired locations. After the adhesive layer 48 is applied to the stent body 20, the anti-migration structure layer 40 and/or 3D structures 30 may be disposed over the adhesive layer 48. Preferably, the anti-migration structure layer 40 and/or 3D structures 30 are adhered to the stent body 20 with use of a combination of heat-shrink adhesive and heat. An alternative method is to place the anti-migration structure layer 40 directly on the stent body 20. After the anti-migration structure layer 40 is placed thereon, the stent body 20 together with the anti-migration structure layer 40 a polymer may be applied to the outer surface thereof. The polymer may be applied in any desired manner, including spraying, rolling, dipping, or the like. Any polymer may be used, and in one embodiment, the polymer includes polyurethane. The anti-migration structure layer 40 may be adhered non-continuously at selected areas, or may be adhered continuously throughout the entire length of the stent body 20. The present<!-- EPO <DP n="31"> --> invention is not limited by above examples. For instance, a strip of melted polymer may be placed either underneath or on top of the anti-migration structure layer 40.</p><p id="p0055" num="0055">Preferably, the fabrication process can also minimize any openings or gaps in the prosthetic device 10, which may allow tissue ingrowth. Ingrowth may breed and develop on any opening or seam in the device 10. Such ingrowth may precipitate a gripping bond between the body lumen and the stent body 20, making it difficult to remove the stent body 20 after a period of time. The adhesion layer 48 of the present invention, possibly in combination with heating or sintering may help ensure that seams or openings are minimized or eliminated altogether.</p><p id="p0056" num="0056">A method of insertion and/or removal of the prosthetic device of the present invention may include various steps. First, a collapsed stent-graft prosthesis may be provided. The prosthesis may have any combination of shape, thickness, and position arrangement as desired, as explained above. The prosthesis is preferably disposed within a delivery device, such as a catheter or any other device. The delivery device may then be inserted into a selected region of a body lumen. For proper placement, markers may be used, including radiopaque markers and the like. Once properly positioned, the collapsed prosthesis may be released from the delivery device and expanded. To achieve expansion, the prosthesis may be self-expanding, or a balloon delivery system may be provided as is known in the art. The delivery device may then be removed. For various reasons, one may wish to remove the prosthesis after placement, in this fashion, a second delivery device may be inserted into the body lumen after placement of the prosthesis.<!-- EPO <DP n="32"> --> This second delivery device preferably includes a grabbing mechanism. The user may then use the second delivery device to remove the prosthesis, desirably without removal of ingrowth generated on the prosthesis.</p><p id="p0057" num="0057">The anti-migration structure layer 40 has been described for creating a friction surface, but it is to be understand that, other types of structures such as non-woven coverings may be used instead of threads to provide the rough surface. For instance, materials such as thin polymers, elastomers, plastic wires, or the metal wires of the stent itself are contemplated as being part of the invention. For instance, the 3D structures 30 can be combined with anti-migration filaments 42, 44 to provide a hybrid anti-migration structure.</p></description><claims mxw-id="PCLM56984045" lang="DE" load-source="patent-office"><!-- EPO <DP n="37"> --><claim id="c-de-01-0001" num="0001"><claim-text>Intraluminale Prothese, die aufweist:
<claim-text>a) eine radial expandierbare röhrenförmige Stentstruktur (20) mit einer Länge, die eine Längsachse festlegt, wobei die röhrenförmige Struktur eine offene Wandstruktur aufweist und eine Innenfläche und eine Außenfläche hat; und</claim-text>
<claim-text>b) eine Polymerabdeckung (22), die auf mindestens einem Abschnitt der Außenfläche der Wandstruktur angeordnet ist und eine darauf gebildete dreidimensionale migrationshemmende Struktur (30) hat, wobei die migrationshemmende Struktur Reibung zwischen der Prothese und dem Lumen erhöhen kann, in dem sie platziert wird;<br/>
wobei die migrationshemmende Struktur aus einer Gruppe ausgewählt ist, die aus Polyethylenterephthalat, Nylon, Polyethylen, Polytetrafluorethylen, Polypropylen, Polyurethan, Polyamid, Silikon und deren Kombinationen besteht.</claim-text></claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Intraluminale Prothese nach Anspruch 1, wobei die Wand geflochtene Stentdrähte aufweist.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Intraluminale Prothese nach Anspruch 1, wobei die migrationshemmende Struktur in der Polymerabdeckung mindestens teilweise eingebettet ist.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Intraluminale Prothese nach Anspruch 1, wobei die migrationshemmende Struktur an einer Stelle angeordnet ist,<!-- EPO <DP n="38"> --> die im Wesentlichen senkrecht zur Längsachse der Prothese ist.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Intraluminale Prothese nach Anspruch 1, wobei die migrationshemmende Struktur ein Muster aufweist, das aus der Gruppe ausgewählt ist, die aus einem Spiralmuster, einem lockeren Gewebemuster, einem durchbrochenen Strickmuster, einem geformten Muster und deren Kombinationen besteht.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Intraluminale Prothese nach Anspruch 1, wobei die Prothese mindestens ein aufgeweitetes Ende hat.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Intraluminale Prothese nach Anspruch 1, wobei die Prothese mindestens ein zulaufendes Ende hat.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Intraluminale Prothese nach Anspruch 6, wobei die migrationshemmende Struktur auf mindestens einem aufgeweiteten Ende angeordnet ist.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Intraluminale Prothese nach Anspruch 7, wobei die migrationshemmende Struktur auf mindestens einem zulaufenden Ende angeordnet ist.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>Intraluminale Prothese nach Anspruch 1, wobei:
<claim-text>a. die Stentstruktur eine offene Hülsenstruktur mit einer festgelegten Länge entlang einer Achse und mit einem festgelegten Querschnittdurchmesser aufweist, wobei die offene Hülsenstruktur eine Außenlumenfläche und eine Innenlumenfläche aufweist; und</claim-text>
<claim-text>b. die migrationshemmende Struktur eine ausreichende Dicke hat, um der offenen Hülsenstruktur migrationshemmende<!-- EPO <DP n="39"> --> Kraft zu verleihen, sobald sie innerhalb eines Lumens gesetzt ist.</claim-text></claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>Intraluminale Prothese nach Anspruch 10, wobei die migrationshemmende Struktur und die offene Hülsenstruktur durch eine dazwischen angeordnete Klebeschicht aneinan-der befestigt sind.</claim-text></claim><claim id="c-de-01-0012" num="0012"><claim-text>Intraluminale Prothese nach Anspruch 10, wobei die offene Hülsenstruktur zwei Enden an entgegengesetzten Enden der Achse und einen Zwischenabschnitt dazwischen aufweist, wobei mindestens ein entgegengesetztes Ende einen aufgeweiteten Abschnitt mit einem breiteren Querschnittdurchmesser als der Querschnittdurchmesser des Zwischenabschnitts bildet.</claim-text></claim><claim id="c-de-01-0013" num="0013"><claim-text>Intraluminale Prothese nach Anspruch 10, ferner mit einer Elastomerschicht, die über mindestens einem Abschnitt der Außenfläche angeordnet ist.</claim-text></claim><claim id="c-de-01-0014" num="0014"><claim-text>Verfahren zur Herstellung eines einstellbaren und/oder entfernbaren Stents, wobei das Verfahren die Schritte aufweist:
<claim-text>spiralförmig und über den Umfang erfolgendes Wickeln mindestens eines länglichen Drahts (12 und 14) im Hinblick auf eine Längsachse, um eine diametral verformbare Hülsenstruktur mit entgegengesetzten offenen Enden und</claim-text>
<claim-text>einer Außenseite zu bilden;</claim-text>
<claim-text>Verkapseln mindestens eines Abschnitts der Hülsenstruktur mit einem Elastomer (22), um mindestens einen teilweise abgedeckten Stent (20) zu bilden; und</claim-text>
<claim-text>Aufbringen einer migrationshemmenden Struktur (30) mit einer optimalen Kombination aus Form, Dicke und Positionsanordnung über der Außenseite, um so Anraureibung zu<!-- EPO <DP n="40"> --> maximieren und Widerstand gegen Einführung und Entfernung zu minimieren;</claim-text>
<claim-text>wobei die migrationshemmende Struktur (30) aus einer Gruppe ausgewählt ist, die aus Polyethylenterephthalat, Nylon, Polyethylen, Polytetrafluorethylen, Polypropylen, Polyurethan, Polyamid, Silikon und deren Kombinationen besteht.</claim-text></claim-text></claim><claim id="c-de-01-0015" num="0015"><claim-text>Verfahren zur Herstellung eines einstellbaren und/oder entfernbaren Stents nach Anspruch 14, wobei das Verfahren ferner den Schritt aufweist:
<claim-text>Auftragen einer Klebeschicht auf mindestens eine Oberfläche der migrationshemmenden Struktur vor Aufbringen der migrationshemmenden Struktur auf die Hülsenstruktur.</claim-text></claim-text></claim></claims><claims mxw-id="PCLM56984046" lang="EN" load-source="patent-office"><!-- EPO <DP n="33"> --><claim id="c-en-01-0001" num="0001"><claim-text>An intraluminal prosthesis comprising:
<claim-text>a) a radially expandable tubular stent structure (20) having a length defining a longitudinal axis, said tubular structure including an open wall structure and having an interior surface and an exterior surface; and</claim-text>
<claim-text>b) a polymeric covering (22) disposed on at least a portion of the exterior surface of said wall structure and having a three-dimensional anti-migration structure (30) formed thereon, the anti-migration structure capable of increasing friction between the prosthesis and the lumen into which it is placed;<br/>
wherein said anti-migration structure is selected from a group consisting of polyethylene terepthalate, nylon, polyethylene, polytetrafluoroethylene, polypropylene, polyurethane, polyamide, silicone, and combinations thereof.</claim-text></claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>An intraluminal prosthesis according to claim 1, wherein said wall comprises braided stent wires.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>An intraluminal prosthesis according to claim 1, wherein said anti-migration structure is at least partially embedded in said polymeric covering.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>An intraluminal prosthesis according to claim 1, wherein said anti-migration structure is disposed at a location that is substantially perpendicular to the longitudinal axis of said prosthesis.<!-- EPO <DP n="34"> --></claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>An intraluminal prosthesis according to claim 1, wherein said anti-migration structure comprises a pattern selected from the group consisting ofa helical pattern, an open weave pattern, an open knit pattern, a molded pattern, and combinations thereof.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>An intraluminal prosthesis according to claim 1, wherein the prosthesis has at least one flared end.</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>An intraluminal prosthesis according to claim 1, wherein the prosthesis has at least one tapered end.</claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>An intraluminal prosthesis according to claim 6, wherein said anti-migration structure is disposed on at least one flared end.</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>An intraluminal prosthesis according to claim 7, wherein said anti-migration structure is disposed on at least one tapered end.</claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>An intraluminal prosthesis according to claim 1, wherein:
<claim-text>a. said stent structure comprises an open sleeve structure of a defined length along an axis and having a defined cross-sectional diameter, said open sleeve structure comprising an exterior luminal surface and an interior luminal surface; and</claim-text>
<claim-text>b. said anti-migration structure has a thickness sufficient to impart anti-migration force to said open sleeve structure once deployed inside a lumen.</claim-text><!-- EPO <DP n="35"> --></claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>An intraluminal prosthesis according to claim 10, wherein said anti-migration structure and said open sleeve structure are attached to each other by an adhesive layer disposed therebetween.</claim-text></claim><claim id="c-en-01-0012" num="0012"><claim-text>An intraluminal prosthesis according to claim 10, wherein said open sleeve structure comprises two ends at opposed ends of said axis and an intermediate portion therebetween, wherein at least one opposed end defines a flared portion having a wider cross-sectional diameter than the cross-sectional diameter of said intermediate portion.</claim-text></claim><claim id="c-en-01-0013" num="0013"><claim-text>An intraluminal prosthesis according to claim 10, further comprising an elastomeric layer disposed over at least a portion of said exterior surface.</claim-text></claim><claim id="c-en-01-0014" num="0014"><claim-text>A method of manufacturing an adjustable and/or removable stent, the method comprising the steps of:
<claim-text>helically and circumferentially winding at least an elongate wire (12 and 14) with respect to a longitudinal axis to form a diametrically deformable sleeve structure having opposed open ends and an exterior side;</claim-text>
<claim-text>encapsulating at least a portion of said sleeve structure with an elastomer (22) to define at least a partially covered stent (20); and</claim-text>
<claim-text>applying an anti-migration structure (30) having an optimal combination of shape, thickness, and position arrangement over said exterior side so as to maximize roughening friction and minimize resistance against insertion and removal;<!-- EPO <DP n="36"> --></claim-text>
<claim-text>wherein said anti-migration structure (30) is selected from a group consisting of polyethylene terepthalate, nylon, polyethylene, polytetrafluoroethylene, polypropylene, polyurethane, polyamide, silicone, and combinations thereof.</claim-text></claim-text></claim><claim id="c-en-01-0015" num="0015"><claim-text>A method of manufacturing an adjustable and/or removable stent according to claim 14, wherein the method further comprises the step of:
<claim-text>applying an adhesive layer to at least one surface of said anti-migration structure prior to applying said anti-migration structure to said sleeve structure.</claim-text></claim-text></claim></claims><claims mxw-id="PCLM56984047" lang="FR" load-source="patent-office"><!-- EPO <DP n="41"> --><claim id="c-fr-01-0001" num="0001"><claim-text>Prothèse intraluminale comprenant :
<claim-text>a) une structure de stent tubulaire expansible radialement (20) ayant une longueur définissant un axe longitudinal, ladite structure tubulaire incluant une structure de paroi ouverte et ayant une surface intérieure et une surface extérieure ; et</claim-text>
<claim-text>b) une couverture polymère (22) disposée sur au moins une partie de la surface extérieure de ladite structure de paroi et ayant une structure anti-migration tridimensionnelle (30) formée sur elle, la structure anti-migration capable d'augmenter le frottement entre la prothèse et la lumière dans laquelle elle est placée ;<br/>
où ladite structure anti-migration est choisie dans un groupe consistant en polyéthylène téréphtalate, Nylon, polyéthylène, polytétrafluoroéthylène, polypropylène, polyuréthane, polyamide, silicone et leurs combinaisons.</claim-text></claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Prothèse intraluminale selon la revendication 1, où ladite paroi comprend des fils de stent tressés.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Prothèse intraluminale selon la revendication 1, où ladite structure anti-migration est au moins partiellement incluse dans ladite couverture polymère.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Prothèse intraluminale selon la revendication 1, où ladite structure anti-migration est disposée à un emplacement qui est sensiblement perpendiculaire à l'axe longitudinal de ladite prothèse.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Prothèse intraluminale selon la revendication 1, où ladite structure anti-migration comprend un motif choisi dans le groupe consistant en un motif hélicoïdal, un motif tissé ouvert, un motif tricoté ouvert, un motif moulé et leurs combinaisons.</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>Prothèse intraluminale selon la revendication 1, où la prothèse a au moins une extrémité évasée.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>Prothèse intraluminale selon la revendication 1, où la prothèse a au moins une extrémité effilée.</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>Prothèse intraluminale selon la revendication 6, où ladite structure anti-migration est disposée sur au moins une extrémité évasée.</claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>Prothèse intraluminale selon la revendication 7, où ladite structure anti-migration est disposée sur au moins une extrémité effilée.<!-- EPO <DP n="42"> --></claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>Prothèse intraluminale selon la revendication 1, où :
<claim-text>a. ladite structure de stent comprend une structure de gaine ouverte d'une longueur définie le long d'un axe et ayant un diamètre en section transversale défini, ladite structure de gaine ouverte comprenant une surface luminale extérieure et une surface luminale intérieure ; et</claim-text>
<claim-text>b. ladite structure anti-migration a une épaisseur suffisante pour conférer une force anti-migration à ladite structure de gaine ouverte une fois déployée à l'intérieur d'une lumière.</claim-text></claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>Prothèse intraluminale selon la revendication 10, où ladite structure anti-migration et ladite structure de gaine ouverte sont fixées l'une à l'autre par une couche adhésive disposée entre elles.</claim-text></claim><claim id="c-fr-01-0012" num="0012"><claim-text>Prothèse intraluminale selon la revendication 10, où ladite structure de gaine ouverte comprend deux extrémités à des extrémités opposées dudit axe et une partie intermédiaire entre elles, où au moins une extrémité opposée définit une partie évasée ayant un diamètre en section transversale plus grand que le diamètre en section transversale de ladite partie intermédiaire.</claim-text></claim><claim id="c-fr-01-0013" num="0013"><claim-text>Prothèse intraluminale selon la revendication 10, comprenant en outre une couche élastomère disposée sur au moins une partie de ladite surface extérieure.</claim-text></claim><claim id="c-fr-01-0014" num="0014"><claim-text>Procédé de fabrication d'un stent ajustable et/ou amovible, le procédé comprenant les étapes de :
<claim-text>enrouler en hélice et sur la circonférence au moins un fil allongé (12 et 14) par rapport à un axe longitudinal pour former une structure de gaine diamétralement déformable ayant des extrémités ouvertes opposées et un côté extérieur ;</claim-text>
<claim-text>encapsuler au moins une partie de ladite structure de gaine avec un élastomère (22) pour définir au moins un stent partiellement couvert (20) ; et</claim-text>
<claim-text>appliquer une structure anti-migration (30) ayant une combinaison optimale de forme, d'épaisseur et d'agencement de position sur ledit côté extérieur de manière à maximiser le frottement rugueux et minimiser la résistance à l'insertion et au retrait ;</claim-text>
<claim-text>où ladite structure anti-migration (30) est choisie dans un groupe consistant en polyéthylène téréphtalate, Nylon, polyéthylène,<!-- EPO <DP n="43"> --> polytétrafluoroéthylène, polypropylène, polyuréthane, polyamide, silicone et leurs combinaisons.</claim-text></claim-text></claim><claim id="c-fr-01-0015" num="0015"><claim-text>Procédé de fabrication d'un stent ajustable et/ou amovible selon la revendication 14, où le procédé comprend en outre l'étape de :
<claim-text>appliquer une couche adhésive à au moins une surface de ladite structure anti-migration avant d'appliquer ladite structure anti-migration à ladite structure de gaine.</claim-text></claim-text></claim></claims><drawings mxw-id="PDW16671732" load-source="patent-office"><!-- EPO <DP n="44"> --><figure id="f0001" num="1"><img id="if0001" file="imgf0001.tif" wi="153" he="152" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="45"> --><figure id="f0002" num="2"><img id="if0002" file="imgf0002.tif" wi="165" he="126" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="46"> --><figure id="f0003" num="3"><img id="if0003" file="imgf0003.tif" wi="155" he="165" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="47"> --><figure id="f0004" num="4"><img id="if0004" file="imgf0004.tif" wi="165" he="123" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="48"> --><figure id="f0005" num="5"><img id="if0005" file="imgf0005.tif" wi="128" he="125" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="49"> --><figure id="f0006" num="6,7"><img id="if0006" file="imgf0006.tif" wi="162" he="173" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="50"> --><figure id="f0007" num="8,9"><img id="if0007" file="imgf0007.tif" wi="165" he="172" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="51"> --><figure id="f0008" num="10,11"><img id="if0008" file="imgf0008.tif" wi="165" he="155" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="52"> --><figure id="f0009" num="12,13"><img id="if0009" file="imgf0009.tif" wi="162" he="152" img-content="drawing" img-format="tif"/></figure></drawings><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
